KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) Other Operating Expenses (2016 - 2023)

Inovio Pharmaceuticals' Other Operating Expenses history spans 8 years, with the latest figure at $10.5 million for Q3 2023.

  • For Q3 2023, Other Operating Expenses changed N/A year-over-year to $10.5 million; the TTM value through Jun 2024 reached $10.5 million, changed N/A, while the annual FY2023 figure was $10.5 million, N/A changed from the prior year.
  • Other Operating Expenses for Q3 2023 was $10.5 million at Inovio Pharmaceuticals, up from $1.0 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $10.5 million in Q3 2023 and bottomed at $10.5 million in Q3 2023.